



## sTNFR1 Test

sTNFR1 accurately identifies diabetic patients at high risk of progression to esrd

- ◆ Improve patient management
- ◆ Standard assay format
- ◆ 50  $\mu$ L serum or plasma
- ◆ Accurate & reliable quantification of sTNFr1

# 20 years after onset of overt nephropathy, ~20% of diabetes patients will have progressed to ESRD [6]

Early detection of diabetic patients that are high-risk for ESRD. Improve Patient Management. Reduce costs and save time.

The EKF sTNFR1 Test is a standard ELISA assay that allows for early and accurate identification of diabetic patients who are at high risk of progression to end stage renal disease (ESRD), representing the potential for significant improvement in patient management and outcomes.

The sTNFR1 test accurately and reliably detects circulating levels of Soluble Tumor Necrosis Factor receptor 1 (sTNFR1) in patient samples. Recent research has demonstrated that high circulating levels of sTNFR1 were strongly associated with progression to ESRD in patients both with and without overt nephropathy.

Advanced Detection	<ul style="list-style-type: none"> <li>Identifies patients at risk of progression to ESRD up to 10 years in advance of currently available tests.</li> </ul>
Easy-to-use	<ul style="list-style-type: none"> <li>Minimal training required. Uses standard laboratory equipment.</li> </ul>
Small Sample Quantity	<ul style="list-style-type: none"> <li>Requires 50 µl Serum or Plasma.</li> </ul>
Accurate & Reliable	<ul style="list-style-type: none"> <li>Uses Monoclonal Antibodies to give accurate results in 4.5 hours. Minimal Interference and no cross reactivity with sTNFR2.</li> </ul>
Improve Patient Management	<ul style="list-style-type: none"> <li>Allows clinicians to identify patients who need the most care. Reduces costs and potentially saves time.</li> </ul>



1

50 µl Serum or Plasma



2

User-Friendly Assay Procedure



3

Accurate & Sensitive Results

## References

Risk of ESRD and All Cause Mortality in Type 2 Diabetes According to Circulating Levels of FGF-23 and TNFR1.

Jung Eun Lee, Gohda T, Walker W, et al. PLoS One. 2013;8(3):e58007.

Baseline Markers of Inflammation Are Associated With Progression to Macroalbuminuria in Type 1 Diabetic Subjects.

Lopes-Virella M, Baker N, DCCT/EDIC Research Group, et al. Diabetes Care. 2013 Mar 20 [ePub ahead of print].

Circulating TNF Receptors 1 and 2 Predict ESRD in Type 2 Diabetes.

Niewczas M, Gohda T, Skupien J, et al. J Am Soc Nephrol. 2012 Mar;23(3):507-15.

Circulating TNF Receptors 1 and 2 Predict Stage 3 CKD in Type 1 Diabetes.

Gohda T, Niewczas M, Ficociello L, et al. J Am Soc Nephrol. 2012 Mar;23(3):516-24.

Serum Concentrations of Markers of TNF and Fas-Mediated Pathways and Renal Function in Nonproteinuric Patients with Type 1 Diabetes.

Niewczas M, Ficociello L, Johnson A, et al. Clin J Am Soc Nephrol. 2009 Jan;4(1):62-70.

American Diabetes Association: Position statement: Nephropathy in Diabetes. Diabetes Care 27 (Suppl 1):S79-83, 2004.

Manufacturer  
Quotient Diagnostics Ltd,  
Russell House - Molesey Road,  
Walton on Thames,  
Surrey,  
KT12 3PE,  
United Kingdom

Sales  
Stanbio Laboratory  
1261 North Main Street, Boerne  
Texas 78006, USA  
+1 830 249 0772  
Email: sales@ekfdiagnostics.com  
www.ekfdiagnostics.com



ISO 13485:2003 &  
EN ISO 13485:2012  
Certificate Number:  
MD 587647



Diagnostics  
for life

Eff date 2.0-06.2015